Hong Kong Interactive Media and Services Stock News

Want Want China Holdings (SEHK:151) is back in focus after releasing full year results to March 31, 2026, together with a proposed lower final ordinary dividend, putting profitability and cash returns to shareholders under the spotlight. See our latest analysis for Want Want China Holdings. The latest earnings and dividend update appears to have sharpened attention on Want Want China Holdings' profitability, with the stock closing at HK$3.24 and a 1-day share price return of 2.53% following a...

Hansoh Pharmaceutical Group (SEHK:3692) has received approval from China's National Medical Products Administration to start clinical trials of its HS-20136-2 injection for type 2 diabetes and obesity, drawing fresh attention to the stock. See our latest analysis for Hansoh Pharmaceutical Group. The clinical trial approval arrives after a sharp swing in sentiment, with Hansoh Pharmaceutical Group’s share price up 17.59% over the past week and 13.09% over 30 days, even though the 90 day share...

Investors who take an interest in AK Medical Holdings Limited ( HKG:1789 ) should definitely note that the VP...

Genertec Universal Medical Group (SEHK:2666) drew investor focus after its annual general meeting on 24 June 2026, where shareholders approved a final dividend of HK$0.36 per share and amendments to the company’s articles of association. See our latest analysis for Genertec Universal Medical Group. At a share price of HK$4.62, Genertec Universal Medical Group has seen short term share price returns pick up, with gains of 3.36% over one day and 5.24% over seven days. However, the 30 day share...

JD Health International Inc. ( HKG:6618 ) saw a double-digit share price rise of over 10% in the past couple of months...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our latest analysis for Alebund Pharmaceuticals (Jiangsu). The strong first day reception for Alebund Pharmaceuticals (Jiangsu) has been followed by a 1 day share price return of 18.75% to HK$30.28, although the share price return year to date is down 34.17%. This suggests short term momentum is...

COSCO SHIPPING Ports Limited ( HKG:1199 ), might not be a large cap stock, but it saw significant share price movement...

Legendary Education Group Limited's ( HKG:8195 ) recent earnings report didn't offer any surprises, with the shares...

Despite posting healthy earnings, China High Speed Transmission Equipment Group Co., Ltd.'s ( HKG:658 ) stock has been...

As you might know, China Water Affairs Group Limited ( HKG:855 ) recently reported its full-year numbers. Statutory...

It looks like China Taiping Insurance Holdings Company Limited ( HKG:966 ) is about to go ex-dividend in the next four...

CARsgen Therapeutics Holdings announced that China’s National Medical Products Administration has approved satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior treatments. As the first CAR T-cell therapy approved globally for solid tumors, satri-cel could reshape treatment options in high-burden cancers like...

With inflation trends uneven across regions and central banks sending mixed signals on rate paths, dependable income can feel hard to find. That is where the Dividend Powerhouses screener comes in, focusing on companies with dividend yields above 5% that are covered by current earnings, growing and relatively stable. While policy debates continue around interest rates, growth and inflation, these stocks aim to put cash in your account today. In this article, you will see three stocks from the...

Shanghai MicroPort MedBot (Group) (SEHK:2252) is in focus after its Toumai Remote laparoscopic surgery robot received the EU CE Mark, opening access to more than 30 European markets and providing formal regulatory recognition of remote surgery. See our latest analysis for Shanghai MicroPort MedBot (Group). The Toumai Remote CE Mark news comes as Shanghai MicroPort MedBot (Group)'s 1 day share price return of 1.57% and 7 day share price return of 4.20% contrast with weaker 30 and 90 day share...

Xiamen Yan Palace Bird's Nest Industry Co., Ltd. ( HKG:1497 ), is not the largest company out there, but it saw a...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Man Wah Holdings Limited ( HKG:1999 ) stock is about to trade ex-dividend in 4 days. The ex-dividend date generally...

As global markets navigate a complex landscape marked by mixed performances in major indices and economic data, investors are increasingly turning their attention to Asia, where resilient manufacturing activity and strategic policy measures are shaping the investment climate. In this context, identifying undervalued stocks that trade below their estimated fair value can offer opportunities for those seeking to capitalize on potential market inefficiencies.

It's been a mediocre week for Want Want China Holdings Limited ( HKG:151 ) shareholders, with the stock dropping 17% to...

Baijin Life Science Holdings (SEHK:1466) has posted its latest full year update with first half FY 2026 revenue of HK$55.1 million and EPS of HK$0.0028, while trailing twelve month figures show revenue of HK$89.3 million and EPS of HK$0.0449 loss alongside a net loss of HK$37.9 million. The company has seen recent half year revenue move from HK$70.9 million in 1H FY 2025 to HK$64.7 million in 2H FY 2025 and HK$55.1 million in 1H FY 2026, with EPS shifting from a HK$0.0092 loss to HK$0.0083...

GoFintech Quantum Innovation (SEHK:290) has put fresh numbers on the table for FY 2026, with first half revenue of HK$1.0b and basic EPS of HK$0.029 setting the tone for how the year is shaping up. The company has seen revenue move from HK$21.3m in the first half of 2025 to HK$838.9m in the second half of 2025 and then to HK$1.0b in the first half of 2026. Basic EPS has shifted from a loss of HK$0.0017 to a small profit of HK$0.0012 and then HK$0.029 across the same periods, giving investors...